These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15353976)

  • 21. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings.
    Ekouevi DK; Inwoley A; Tonwe-Gold B; Danel C; Becquet R; Viho I; Rouet F; Dabis F; Anglaret X; Leroy V
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1469-74. PubMed ID: 18160003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.
    Walker AS; Doerholt K; Sharland M; Gibb DM;
    AIDS; 2004 Sep; 18(14):1915-24. PubMed ID: 15353977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory manifestations in HIV-infected children pre- and post-HAART in Abidjan, the Ivory Coast.
    Kouakoussui A; Fassinou P; Anaky MF; Elenga N; Laguide R; Wemin ML; Toure R; Menan H; Rouet F; Msellati P
    Paediatr Respir Rev; 2004 Dec; 5(4):311-5. PubMed ID: 15531256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.
    Nacro B; Zoure E; Hien H; Tamboura H; Rouet F; Ouiminga A; Drabo A; Yameogo S; Hien A; Peyriere H; Mathieu O; Hirt D; Treluyer JM; Nicolas J; Foulongne V; Segondy M; van de Perre P; Diagbouga S; Msellati P
    Bull World Health Organ; 2011 Jun; 89(6):451-8. PubMed ID: 21673861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.
    Danel C; Moh R; Minga A; Anzian A; Ba-Gomis O; Kanga C; Nzunetu G; Gabillard D; Rouet F; Sorho S; Chaix ML; Eholié S; Menan H; Sauvageot D; Bissagnene E; Salamon R; Anglaret X;
    Lancet; 2006 Jun; 367(9527):1981-9. PubMed ID: 16782488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012.
    Palladino C; Briz V; Bellón JM; Climent FJ; de Ory SJ; Mellado MJ; Navarro ML; Ramos JT; Taveira N; de José MI; Muñoz-Fernández MÁ;
    PLoS One; 2014; 9(5):e96307. PubMed ID: 24788034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children.
    Singh R; Mukherjee A; Singla M; Das BK; Kabra SK; Lodha R
    Indian J Pediatr; 2017 Dec; 84(12):893-896. PubMed ID: 28875475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
    Banerjee T; Pensi T; Banerjee D; Grover G
    Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of lipid levels in HIV-infected children treated or not with HAART in Abidjan, Cote d'Ivoire.
    Cournil A; Mercier-Deheuvels S; Dupuy AM; Cristol JP; Anaky MF; Rouet F; Fassinou P; Msellati P
    J Trop Pediatr; 2012 Feb; 58(1):43-9. PubMed ID: 21558308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of dried blood spot diagnosis using HIV1-DNA and HIV1-RNA Biocentric assays in infants in Abidjan, Côte d'Ivoire. The Pedi-Test DBS ANRS 12183 Study.
    Yapo V; d'Aquin Toni Td; Desmonde S; Amani-Bosse C; Oga M; Lenaud S; Menan H; Timité-Konan M; Leroy V; Rouzioux C
    J Virol Methods; 2013 Nov; 193(2):439-45. PubMed ID: 23872283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of highly active antiretroviral therapy in HIV-infected Indian children.
    Mukherjee A; Shah N; Singh R; Vajpayee M; Kabra SK; Lodha R
    BMC Infect Dis; 2014 Dec; 14():701. PubMed ID: 25539905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278).
    Boullé C; Rouet F; Fassinou P; Msellati P; Debeaudrap P; Chaix ML; Rouzioux C; Avettand-Fenoel V
    J Antimicrob Chemother; 2014 Nov; 69(11):3047-50. PubMed ID: 25038068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.
    Hanson DL; Adjé-Touré C; Talla-Nzussouo N; Eby P; Borget MY; Kouadio LY; Celestin BE; Tossou O; Eholie S; Kadio A; Chorba T; Nkengasong JN
    AIDS Res Hum Retroviruses; 2009 May; 25(5):489-95. PubMed ID: 19388820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.
    Wamalwa DC; Obimbo EM; Farquhar C; Richardson BA; Mbori-Ngacha DA; Inwani I; Benki-Nugent S; John-Stewart G
    BMC Pediatr; 2010 May; 10():33. PubMed ID: 20482796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.